Latest News
ORLADEYO (oral treatment) is recommended for reimbursement in Quebec
Institut national d'excellence en santé et services sociaux (INESSS), whose missions is "to promote clinical
TAKHZYRO available through Veterans Affairs Canada
Qualifying HAE patients who access treatments through Veterans Affairs Canada (VAC) now have access to
TAKHZYRO available in PEI
Great news for eligible HAE patients in PEI. Lanadelumab (TAKHZYRO), a subcutaneous injection to routinely
Improved access to affordable and effective drugs for rare diseases in Canada
On March 22, 2023, the Canadian federal government announced their plan to provide up to
CADTH Recommends Reimbursement for ORLADEYO
We are thrilled to share that the Canadian Agency for Drugs and Technologies in Heath
Rare Disease Day Breakfast with CORD
To honour Rare Disease Day 2023, HAE Canada President, and Ontario Regional Director, Michelle Cooper,
HAEC Board member featured in Canada’s Rare Voices 2023
For Canada's Rare Voices 2023, Patient Voice teamed up with 12 patients and their families,
Updates to our Board of Directors
We have some announcements to make about the HAE Canada Board of Directors. The 2022-2023
2022 HAEi Global Leadership Workshop
Traditionally, every two years, HAE International (HAEi) hosted the HAE Global Conference where patients, caregivers,
CBS Announces Results of the RFP for PPRP
Canadian Blood Services (CBS) Announces the Results of the Request for Proposals (RFP) for Plasma-Derived
Support Family Testing
Give valuable insights in HAE science
Hereditary Angioedema (HAE) is a hereditary disorder. It is therefore very important to have other family members tested. To help you in this process HAE International has developed two documents for patients. You can download the documents below:
